May 11, 2024 AppLovin Joins Elite 100% Return Club!
Apple: Here’s My Price Target And WWDC Strategy
Tesla Is Selling More Than Cars With FSD
Nvidia Faces Macro Headwinds And Micro Tailwinds
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
Novavax (NVAX) Stock Forecast for 2024–2028. Sell or Buy?
Updated: May 18, 2024 (15:36)
Sector: HealthcareThe share price of Novavax, Inc. (NVAX) now
50/200 Day Moving Average: $5.38 / $5.93
This figure corresponds to the Average Price over the previous 50/200 days. For Novavax stocks, the 50-day moving average is the support level today.
For Novavax stocks, the 200-day moving average is the support level today.
Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2024, 2025, 2026, 2027, 2028. How much will one Novavax share be worth in 2024 - 2028?
When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock? We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.
Historical and forecast chart of Novavax stock
The chart below shows the historical price of Novavax stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.
Long-term forecasts by years.
A Renaissance in NVAX Stock: The Sanofi Catalyst and Beyond
For investors and analysts tracking Novavax (NVAX), the horizon seems particularly vibrant, pulsing with a mix of challenges and breakthrough opportunities that can sway the NVAX stock price prediction in considerable ways. Central to these developments is the groundbreaking licensing agreement with pharmaceutical titan Sanofi, a strategic partnership poised to inject not only a significant upfront capital boost but also sustained revenue streams through royalties. This collaboration, potentially valued up to $1.2 billion, represents a seismic shift, securing Novavax a coveted spot on the global vaccine stage and fundamentally altering the NVAX stock forecast.
The Pillars of Prediction: Analyzing NVAX's Future Stock Trajectory
To adeptly navigate the Novavax narrative and make informed decisions regarding whether NVAX is a good stock to buy, analysts would do well to dissect the multifaceted aspects influencing its stock rate. Foremost is the Sanofi pact, a veritable game-changer that lends immediate credence and financial bulwark to Novavax. This development alone could serve as a lighthouse, guiding NVAX stock price target adjustments and investor sentiment. Coupled with the recent earnings surpassing EPS expectations, despite a revenue miss, and the strategic forward march in their vaccine pipeline, these elements collectively paint a picture of a company on the verge of a bullish break.
Yet, for a rounded NVAX stock buy or sell analysis, one cannot overlook the inherent challenges—the rigors of market competition, the intricacies of regulatory navigations, and the integration of innovative vaccine technologies into the broader market. These factors, while possibly casting shadows, can also offer the astute analyst a nuanced understanding of the NVAX landscape, enabling a sharper NVAX stock price prediction.
Descending in order of importance, the licensing agreement with Sanofi undoubtedly is the celestial event in the NVAX stock forecast galaxy. Not far behind, the company's financial stability and promising pipeline development cast significant rays of hope for those pondering if NVAX is a good stock to buy. Regulatory trials and market competition, while certainly crucial, somewhat dim in comparison but should not be ignored by any looking to make a buy or sell Novavax stock decision.
In essence, tapping into the most accurate foresight into NVAX's stock trajectory requires a balanced analysis, weighing the monumental partnership with Sanofi against the backdrop of financial, developmental, and market dynamics. These considerations are paramount for those looking to target the NVAX stock price with precision, offering a blueprint for navigating the promising yet unpredictable terrain of Novavax's stock future.
Review the original AnalysisRiding the Wave: How Novavax's Strategic Pivot and Sanofi Alliance Could Surge NVAX Stock
As industry analysts peer into the crystal ball to forecast NVAX stock rates, a few critical events and factors emerge as pivotal in shaping the trajectory of Novavax's stock in the near future. At the heart of this anticipation is Novavax's strategic partnership with pharmaceutical behemoth, Sanofi. This collaboration isn't just a lifeline; it's a potent catalyst that injects not only crucial financial support but also a dose of confidence among investors regarding Novavax's fiscal stability and future prospects.
Zooming into the Future: Key Drivers of NVAX Stock Predictions
Understanding the factors that will most influence the change of NVAX stocks rate is crucial for making the most accurate predictions. These include:
- Financial support from the Sanofi collaboration: The equity investments, alongside upfront and milestone payments from Sanofi, signal a brighter financial forecast for Novavax. Analysts eyeing the NVAX stock forecast recognize this as a pivot point, potentially marking the commencement of an upward trajectory for NVAX stock prices.
- Competition in the combination vaccine market: With the race to market combination COVID-19 and influenza vaccines heating up, the positioning of Novavax against giants like Pfizer and Moderna becomes a critical variable. An analyst pondering 'is NVAX a good stock to buy' will keenly evaluate Novavax’s strategies to compete and carve out market share in this arena.
- Shift in strategy to licensing technology: Novavax's move to license its technology to Sanofi marks a strategic shift. For someone analyzing the NVAX stock price prediction, this approach suggests a reduction in development risk but also raises questions about long-term competitive positioning and royalty income potential.
For those pondering 'buy or sell Novavax stock,' these factors provide a compass by which to navigate. The NVAX stock forecast hinges on the successful execution of its partnership with Sanofi, its competitive acumen in the vaccine market, and the fruits of its licensing strategy. As these dynamics unfold, they offer analysts a blueprint to forecast the NVAX stock rates with a higher degree of certainty, speculating on whether NVAX stock is a buy or sell, and predicting future stock price targets.
Review the original AnalysisNovavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May 20 | 13.03 | 12.80 | 13.58 | 6.14 |
May 21 | 12.66 | 12.08 | 12.92 | 6.98 |
May 22 | 11.52 | 11.15 | 11.76 | 5.49 |
May 23 | 11.21 | 10.47 | 11.86 | 13.29 |
May 24 | 11.24 | 10.61 | 12.05 | 13.54 |
May 25 | 10.85 | 10.47 | 11.05 | 5.50 |
May 26 | 11.21 | 10.70 | 11.95 | 11.69 |
May 27 | 10.80 | 10.54 | 11.45 | 8.67 |
May 28 | 10.36 | 9.99 | 10.90 | 9.06 |
May 29 | 9.93 | 9.73 | 10.57 | 8.63 |
May 30 | 9.81 | 9.63 | 10.27 | 6.60 |
May 31 | 10.62 | 10.31 | 11.21 | 8.72 |
Jun 01 | 10.35 | 9.75 | 10.72 | 9.94 |
Jun 02 | 10.01 | 9.69 | 10.26 | 5.85 |
Jun 03 | 10.68 | 9.92 | 11.25 | 13.47 |
Jun 04 | 11.33 | 10.68 | 12.15 | 13.75 |
Jun 05 | 12.17 | 11.50 | 12.77 | 11.05 |
Jun 06 | 11.99 | 11.21 | 12.69 | 13.18 |
Jun 07 | 11.03 | 10.73 | 11.44 | 6.57 |
Jun 08 | 10.65 | 10.41 | 11.36 | 9.12 |
Jun 09 | 11.01 | 10.47 | 11.38 | 8.70 |
Jun 10 | 10.30 | 9.92 | 10.63 | 7.10 |
Jun 11 | 9.85 | 9.47 | 10.51 | 10.95 |
Jun 12 | 9.63 | 9.45 | 9.88 | 4.49 |
Jun 13 | 10.00 | 9.37 | 10.56 | 12.68 |
Jun 14 | 10.28 | 10.09 | 10.73 | 6.32 |
Jun 15 | 9.50 | 8.89 | 9.97 | 12.22 |
Jun 16 | 9.12 | 8.77 | 9.45 | 7.67 |
Jun 17 | 8.68 | 8.10 | 8.94 | 10.32 |
Jun 18 | 8.48 | 8.21 | 8.99 | 9.48 |
Novavax Daily Price Targets
Novavax Stock Forecast 05-20-2024.
Forecast target price for 05-20-2024: $13.03.
Positive dynamics for Novavax shares will prevail with possible volatility of 5.785%.
Pessimistic target level: 12.80
Optimistic target level: 13.58
Novavax Stock Forecast 05-21-2024.
Forecast target price for 05-21-2024: $12.66.
Negative dynamics for Novavax shares will prevail with possible volatility of 6.525%.
Pessimistic target level: 12.08
Optimistic target level: 12.92
Novavax Stock Forecast 05-22-2024.
Forecast target price for 05-22-2024: $11.52.
Negative dynamics for Novavax shares will prevail with possible volatility of 5.202%.
Pessimistic target level: 11.15
Optimistic target level: 11.76
Novavax Stock Forecast 05-23-2024.
Forecast target price for 05-23-2024: $11.21.
Negative dynamics for Novavax shares will prevail with possible volatility of 11.734%.
Pessimistic target level: 10.47
Optimistic target level: 11.86
Novavax Stock Forecast 05-24-2024.
Forecast target price for 05-24-2024: $11.24.
Positive dynamics for Novavax shares will prevail with possible volatility of 11.922%.
Pessimistic target level: 10.61
Optimistic target level: 12.05
Novavax Stock Forecast 05-25-2024.
Forecast target price for 05-25-2024: $10.85.
Negative dynamics for Novavax shares will prevail with possible volatility of 5.217%.
Pessimistic target level: 10.47
Optimistic target level: 11.05
NVAX (NVAX) Monthly Stock Prediction for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun. | 14.84 | 13.29 | 16.31 | 18.56 |
Jul. | 14.62 | 12.03 | 17.60 | 31.64 |
Aug. | 13.39 | 11.26 | 14.32 | 21.33 |
Sep. | 11.42 | 9.71 | 14.13 | 31.29 |
Oct. | 12.42 | 11.04 | 15.10 | 26.89 |
Nov. | 11.93 | 10.93 | 12.94 | 15.50 |
Dec. | 11.68 | 9.97 | 12.45 | 19.98 |
Novavax forecast for this year
Novavax Stock Prediction for Jun 2024
An uptrend is forecast for this month with an optimal target price of $14.8444. Pessimistic: $13.29. Optimistic: $16.31
Novavax Stock Prediction for Jul 2024
An downtrend is forecast for this month with an optimal target price of $14.6217. Pessimistic: $12.03. Optimistic: $17.60
Novavax Stock Prediction for Aug 2024
An downtrend is forecast for this month with an optimal target price of $13.3935. Pessimistic: $11.26. Optimistic: $14.32
Novavax Stock Prediction for Sep 2024
An downtrend is forecast for this month with an optimal target price of $11.4247. Pessimistic: $9.71. Optimistic: $14.13
Novavax Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $12.4186. Pessimistic: $11.04. Optimistic: $15.10
Novavax Stock Prediction for Nov 2024
An downtrend is forecast for this month with an optimal target price of $11.9343. Pessimistic: $10.93. Optimistic: $12.94
Novavax Stock Prediction for Dec 2024
An downtrend is forecast for this month with an optimal target price of $11.6837. Pessimistic: $9.97. Optimistic: $12.45
Novavax (NVAX) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 11.61 | 9.42 | 12.83 | 26.61 |
Feb | 10.95 | 9.31 | 12.69 | 26.66 |
Mar | 8.06 | 6.51 | 9.44 | 31.00 |
Apr | 7.41 | 6.94 | 7.92 | 12.35 |
May | 5.81 | 5.11 | 6.91 | 25.99 |
Jun | 5.22 | 4.57 | 5.76 | 20.63 |
Jul | 6.39 | 5.24 | 7.27 | 27.94 |
Aug | 5.91 | 4.93 | 6.67 | 26.04 |
Sep | 5.86 | 5.10 | 6.45 | 20.96 |
Oct | 7.58 | 6.35 | 8.62 | 26.36 |
Nov | 8.71 | 7.85 | 10.28 | 23.64 |
Dec | 8.19 | 6.74 | 9.32 | 27.68 |
Novavax (NVAX) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 7.04 | 6.45 | 7.82 | 17.55 |
Feb | 6.80 | 5.76 | 7.68 | 24.98 |
Mar | 7.36 | 5.86 | 8.50 | 31.14 |
Apr | 6.21 | 5.07 | 7.57 | 32.98 |
May | 7.66 | 6.24 | 9.04 | 31.02 |
Jun | 7.94 | 6.70 | 9.77 | 31.44 |
Jul | 7.48 | 6.38 | 8.88 | 28.08 |
Aug | 8.83 | 8.20 | 10.90 | 24.80 |
Sep | 8.96 | 7.30 | 9.64 | 24.28 |
Oct | 9.72 | 7.79 | 10.39 | 24.98 |
Nov | 10.10 | 8.64 | 11.07 | 21.90 |
Dec | 7.40 | 6.38 | 7.98 | 20.04 |
Novavax (NVAX) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 7.82 | 6.67 | 8.43 | 20.87 |
Feb | 6.67 | 5.93 | 7.95 | 25.42 |
Mar | 6.33 | 5.38 | 7.60 | 29.23 |
Apr | 8.06 | 6.66 | 8.59 | 22.51 |
May | 9.05 | 8.26 | 10.44 | 20.81 |
Jun | 9.65 | 8.69 | 11.94 | 27.16 |
Jul | 12.40 | 11.06 | 13.22 | 16.32 |
Aug | 14.67 | 12.07 | 15.59 | 22.58 |
Sep | 13.61 | 10.92 | 14.59 | 25.19 |
Oct | 14.72 | 11.23 | 17.76 | 36.79 |
Nov | 15.29 | 12.31 | 18.04 | 31.78 |
Dec | 13.64 | 12.37 | 16.42 | 24.67 |
Novavax (NVAX) Monthly Stock Prediction for 2028
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 13.56 | 11.73 | 15.75 | 25.56 |
Feb | 16.08 | 12.75 | 18.78 | 32.11 |
Mar | 20.56 | 16.18 | 22.54 | 28.19 |
Apr | 18.16 | 16.80 | 20.99 | 19.98 |
May | 21.75 | 20.12 | 24.30 | 17.19 |
Jun | 24.49 | 21.41 | 28.83 | 25.74 |
Jul | 26.99 | 24.64 | 28.61 | 13.87 |
Aug | 24.24 | 19.58 | 29.40 | 33.39 |
Sep | 23.73 | 19.60 | 28.64 | 31.57 |
Oct | 27.29 | 23.36 | 32.69 | 28.55 |
Nov | 22.13 | 20.21 | 24.26 | 16.70 |
Dec | 16.22 | 13.01 | 19.29 | 32.55 |
Novavax information and performance
20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Market capitalization of the Novavax, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NVAX shares in the company outstanding by the market price of one share.
EBITDA of Novavax is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Novavax (NVAX) stock dividend
Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.